Last $55.56 USD
Change Today +0.91 / 1.67%
Volume 600.7K
CYBX On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 8:10 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

cyberonics inc (CYBX) Snapshot

Open
$54.55
Previous Close
$54.65
Day High
$55.92
Day Low
$54.38
52 Week High
02/14/14 - $73.52
52 Week Low
11/20/14 - $48.19
Market Cap
1.5B
Average Volume 10 Days
446.2K
EPS TTM
$2.37
Shares Outstanding
26.3M
EX-Date
--
P/E TM
23.4x
Dividend
--
Dividend Yield
--
Current Stock Chart for CYBERONICS INC (CYBX)

cyberonics inc (CYBX) Related Bloomberg News

View More Bloomberg News

cyberonics inc (CYBX) Related Businessweek News

No Related Businessweek News Found

cyberonics inc (CYBX) Details

Cyberonics, Inc., together with its subsidiaries, designs, develops, markets, and sells implantable medical devices to hospitals and ambulatory surgery centers. The company offers vagus nerve stimulation (VNS) therapy system that uses pulsed electrical signals applied to the vagus nerve for the treatment of refractory epilepsy and treatment-resistant depression. It is also engaged in investigating the use of VNS and other neuromodulation therapy for other indications, including chronic heart failure, and developing non-implantable device solutions for the management of epilepsy. The company sells its products directly, as well as through independent distributors in Europe, Canada, Mexico, Australia, parts of Central and South America, the Middle East, China, Japan, and other parts of Asia. Cyberonics, Inc. was founded in 1987 and is headquartered in Houston, Texas.

639 Employees
Last Reported Date: 06/16/14
Founded in 1987

cyberonics inc (CYBX) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $613.7K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $334.1K
Chief Operating Officer and Senior Vice Presi...
Total Annual Compensation: $186.6K
Chief Administrative Officer, Senior Vice Pre...
Total Annual Compensation: $318.1K
Senior Vice President of Research & Developme...
Total Annual Compensation: $307.3K
Compensation as of Fiscal Year 2014.

cyberonics inc (CYBX) Key Developments

Cyberonics Reports Consistently Positive Results from the E-36 and E-37 Studies for VNS Therapy Delivered by Aspiresr® Generator

Cyberonics Inc. announced new results from two multi-site clinical studies of the AspireSR generator, E-36 (NCT01325623) and E-37 (NCT01846741), at the AES Annual Meeting in Seattle, Washington. The AspireSR generator is currently investigational in the U.S. and not approved for commercial use. The AspireSR generator attained the CE Mark and is now available in an increasing number of European countries. Investigators presented results from the European E-36 study and the U.S. E-37 study, which assessed the acute impact of the AspireSR generator on seizure duration and termination, as well as the long-term evaluation of safety, clinical benefit of the automatic stimulation feature, and quality of life. Assessments of seizure severity and quality of life were made using validated scales scored by patients, and physicians. The acute impact of the AspireSR generator on seizure duration and termination was evaluated during the Epilepsy Monitoring Unit stay period experienced by all patients in both studies. Seizure activity was recorded using concurrent video-EEG and ECG monitoring. Patients in both studies experienced termination of seizures as well as reduced seizure duration during automatic stimulation compared to historical controls. During three- and six-month follow-up, patients in both studies experienced clinically significant reduction in several key components of seizure activity compared to baseline, including overall seizure severity, movements that could result in harm, and various aspects of post-ictal recovery.

Cyberonics Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 10:30 AM

Cyberonics Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 10:30 AM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Gregory H. Browne, Chief Financial Officer, Principal Accounting Officer and Senior Vice President of Finance.

Cyberonics Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended October 24, 2014; Provides Earnings Guidance for the Fiscal Year 2015

Cyberonics Inc. announced unaudited consolidated earnings results for the second quarter and six months ended October 24, 2014. For the quarter, the company reported net sales of $73,417,194 compared to $70,101,119 for the same period a year ago. Income from operations was $26,261,700 compared to $21,887,638 for the same period a year ago. Income before income tax was $26,297,733 compared to $21,892,364 for the same period a year ago. Net income was $17,273,190 compared to $13,888,462 for the same period a year ago. Diluted income per share was $0.64 compared to $0.50 for the same period a year ago. Adjusted non-GAAP income from operations was $26,261,700 compared to $21,887,638 for the same period a year ago. Adjusted non-GAAP net income was $16,938,730 compared to $13,888,462 for the same period a year ago. Adjusted non-GAAP diluted income per share was $0.63 compared to $0.50 for the same period a year ago. Adjusted EBITDA was $30,393,865 compared to $25,833,135 for the same period a year ago. For the twenty-six weeks, the company reported net sales of $145,421,160 compared to $138,973,476 for the same period a year ago. Income from operations was $48,264,914 compared to $35,491,680 for the same period a year ago. Income before income tax was $48,510,068 compared to $35,409,130 for the same period a year ago. Net income was $30,792,012 compared to $22,562,388 for the same period a year ago. Diluted income per share was $1.15 compared to $0.81 for the same period a year ago. Net cash provided by operating activities was $42,628,686 compared to $22,117,082 for the same period a year ago. Purchases of property, plant and equipment were $3,865,818 compared to $9,050,473 for the same period a year ago. Adjusted non-GAAP income from operations was $48,264,914 compared to $41,466,658 for the same period a year ago. Adjusted non-GAAP net income was $31,262,658 compared to $26,417,594 for the same period a year ago. Adjusted non-GAAP diluted income per share was $1.16 compared to $0.95 for the same period a year ago. Adjusted EBITDA was $57,470,136 compared to $49,922,655 for the same period a year ago. The company is adjusting fiscal 2015 guidance for net sales while maintaining guidance for income from operations, adjusted net income and adjusted diluted earnings per share as follows: Net sales are now expected to be in the range of $292 million to $298 million (previous guidance of $300 million to $307 million). Gross profit margin is expected to be between 90.5% and 91.0%. Income from operations is still expected to be in the range of $96 million to $99 million. The company now anticipates an adjusted effective tax rate of between 35% and 35.5% for fiscal 2015, which assumes the renewal of the R & D tax credit. Adjusted net income for fiscal 2015 is still expected to be in the range of $62 million to $64 million. The company expects adjusted diluted earnings per share will remain in the range of $2.33 to $2.39.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CYBX:US $55.56 USD +0.91

CYBX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ICU Medical Inc $83.77 USD -0.18
RTI Surgical Inc $5.48 USD +0.17
Thoratec Corp $32.64 USD +0.03
Tornier NV $26.55 USD +0.11
Wright Medical Group Inc $27.85 USD -0.17
View Industry Companies
 

Industry Analysis

CYBX

Industry Average

Valuation CYBX Industry Range
Price/Earnings 23.8x
Price/Sales 5.1x
Price/Book 5.4x
Price/Cash Flow 23.2x
TEV/Sales 4.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CYBERONICS INC, please visit www.cyberonics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.